NASDAQ:SCLX

Scilex (SCLX) Stock Price, News & Analysis

$1.20
+0.30 (+33.33%)
(As of 12:17 PM ET)
Today's Range
$0.98
$1.25
50-Day Range
$0.75
$1.61
52-Week Range
$0.73
$8.37
Volume
2.76 million shs
Average Volume
924,659 shs
Market Capitalization
$217.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Scilex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
407.6% Upside
$6.00 Price Target
Short Interest
Bearish
8.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Scilex in the last 14 days
Based on 17 Articles This Week
Insider Trading
Acquiring Shares
$121,521 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.31 out of 5 stars

Medical Sector

582nd out of 918 stocks

Biological Products, Except Diagnostic Industry

94th out of 155 stocks

SCLX stock logo

About Scilex Stock (NASDAQ:SCLX)

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

SCLX Stock Price History

SCLX Stock News Headlines

Scilex Holding (NASDAQ:SCLX) Insider Acquires $69,771.24 in Stock
Scilex (NASDAQ:SCLX) Shares Down 5.9%
SCLX Apr 2024 2.000 put
See More Headlines
Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
5/19/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SCLX
Fax
N/A
Employees
105
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+566.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-114,330,000.00
Net Margins
-229.47%
Pretax Margin
-229.46%

Debt

Sales & Book Value

Annual Sales
$46.74 million
Book Value
($1.05) per share

Miscellaneous

Free Float
165,372,000
Market Cap
$163.07 million
Optionable
Optionable
Beta
0.91
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 60)
    Executive Chairman
    Comp: $885.43k
  • Mr. Stephen Ma (Age 51)
    Senior VP, CFO & Corporate Secretary
    Comp: $708.78k
  • Mr. Jaisim Shah (Age 64)
    President, CEO & Director
    Comp: $785.73k
  • Dr. Suketu D. Desai Ph.D. (Age 58)
    CTO & Senior VP
  • Ms. Gigi DeGuzman
    Executive Director of Administrative Operations & Head of Human Resources
  • Mr. Steven F. Lincoln J.D.
    General Counsel & Chief Compliance Officer
  • Mr. Sumant Rajendran
    Executive Director of Marketing
  • Mike Ciaffi
    National Sales Director
  • Mr. Suresh K. Khemani (Age 64)
    Senior VP & Chief Commercial Officer
    Comp: $456.82k
  • Dr. Dmitri V. Lissin M.D. (Age 64)
    Senior VP & Chief Medical Officer
    Comp: $528.83k

SCLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Scilex stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCLX shares.
View SCLX analyst ratings
or view top-rated stocks.

What is Scilex's stock price target for 2024?

2 brokerages have issued 1-year target prices for Scilex's stock. Their SCLX share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 407.6% from the stock's current price.
View analysts price targets for SCLX
or view top-rated stocks among Wall Street analysts.

How have SCLX shares performed in 2024?

Scilex's stock was trading at $2.04 at the beginning of the year. Since then, SCLX stock has decreased by 42.1% and is now trading at $1.1821.
View the best growth stocks for 2024 here
.

When is Scilex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our SCLX earnings forecast
.

How were Scilex's earnings last quarter?

Scilex Holding (NASDAQ:SCLX) released its earnings results on Monday, March, 11th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $11.43 million.

What ETFs hold Scilex's stock?
Who are Scilex's major shareholders?

Scilex's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.40%), Cannon Global Investment Management LLC (0.02%) and Collective Family Office LLC (0.01%). Insiders that own company stock include Jaisim Shah and Jay Chun.
View institutional ownership trends
.

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCLX) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners